{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:22:24Z","timestamp":1787750544284,"version":"build-2784847793"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multidrug resistance (MDR) remains a major challenge in the effective treatment of breast cancer, often leading to therapeutic failure, tumor recurrence, and poor clinical outcomes. Multiple mechanisms contribute to MDR, including overexpression of ATP-binding cassette (ABC) transporters, evasion of apoptosis, epithelial\u2013mesenchymal transition (EMT), and the persistence of cancer stem cells (CSCs). In recent years, nanomedicine has emerged as a promising strategy to overcome these resistance pathways by enhancing drug delivery, improving intracellular drug accumulation, and enabling targeted and combination therapies.<\/jats:p>\n                  <jats:p>This review provides a comprehensive overview of nanomedicine-based approaches for overcoming MDR in breast cancer. Various nanocarrier systems, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric nanoparticles, inorganic nanocarriers, nanoemulsions, and ligand-targeted systems, are systematically discussed in terms of their design, drug delivery capabilities, and role in bypassing resistance mechanisms. Particular emphasis is placed on combination nanotherapeutic strategies, such as co-delivery of chemotherapeutic agents with natural compounds, gene modulators, or sensitizers, which have demonstrated enhanced efficacy in both in vitro and in vivo models.<\/jats:p>\n                  <jats:p>In addition, this review critically evaluates the limitations of current preclinical studies and highlights key challenges in clinical translation, including variability of the enhanced permeability and retention (EPR) effect, safety concerns, and large-scale manufacturing issues. Overall, nanomedicine offers a multifaceted and promising approach to overcome MDR in breast cancer; however, further translational and clinical studies are required to fully realize its therapeutic potential.<\/jats:p>","DOI":"10.1186\/s43046-026-00400-8","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:54:23Z","timestamp":1787748863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanomedicine strategies for overcoming multidrug resistance in breast cancer: recent advances and future perspectives"],"prefix":"10.1186","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6301-7602","authenticated-orcid":false,"given":"Mohit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2145-756X","authenticated-orcid":false,"family":"Tejaswi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bangwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"400_CR1","unstructured":"World Health Organisation. The global cancer observatory, source: Globocan 2020, 356-india-fact-sheets.pdf. Factsheet India. World Health Organisation; 2021. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/356-india-fact-sheets.pdf. Accessed 17 Jan 2023."},{"issue":"5","key":"400_CR2","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/cancers14051198","volume":"14","author":"AI Fraguas-Sanchez","year":"2022","unstructured":"Fraguas-Sanchez AI, Lozza I, Torres-Suarez AI. Actively targeted nanomedicines in breast cancer: From pre-clinal investigation to clinic. Cancers (Basel). 2022;14(5):1198. https:\/\/doi.org\/10.3390\/cancers14051198.","journal-title":"Cancers (Basel)"},{"key":"400_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.phymed.2018.09.008","volume":"53","author":"CC Wang","year":"2019","unstructured":"Wang CC, Wang J-Y, Lee T-E, et al. Tenulin and isotenulin inhibit P-glycoprotein function and overcome multidrug resistance in cancer cells. Phytomedicine. 2019;53:252\u201362.","journal-title":"Phytomedicine"},{"key":"400_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/21691401.2018.1559182","volume":"47","author":"P Yazdani","year":"2019","unstructured":"Yazdani P, Mansouri E, Eyvazi S, et al. Layered double hydroxide nanoparticles as an appealing nanoparticle in gene\/plasmid and drug delivery system in C2C12 myoblast cells. Artif Cells Nanomed Biotechnol. 2019;47:436\u201342.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"400_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s002329900305","volume":"160","author":"FJ Sharom","year":"1997","unstructured":"Sharom FJ. The P-glycoprotein efflux pump: How does it transport drugs? J Membr Biol. 1997;160:161\u201375. [CrossRef].","journal-title":"J Membr Biol"},{"key":"400_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0306-3623(96)00081-X","volume":"27","author":"O Fardel","year":"1996","unstructured":"Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol. 1996;27:1283\u201391. [CrossRef].","journal-title":"Gen Pharmacol"},{"key":"400_CR7","doi-asserted-by":"crossref","unstructured":"Sharom FJ. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105\u201327. [CrossRef].","DOI":"10.2217\/14622416.9.1.105"},{"key":"400_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/1078-0432.CCR-09-1321","volume":"16","author":"JS Lagas","year":"2010","unstructured":"Lagas JS, Fan L, Wagenaar E, Vlaming ML, van Tellingen O, Beijnen JH, Schinkel AH. P-glycoprotein (P-gp\/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res. 2010;16:130\u201340. [CrossRef].","journal-title":"Clin Cancer Res"},{"key":"400_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","volume":"370","author":"Z Chen","year":"2016","unstructured":"Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L, Li J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016;370:153\u201364. [CrossRef].","journal-title":"Cancer Lett"},{"key":"400_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/jnci\/91.5.429","volume":"91","author":"DD Ross","year":"1999","unstructured":"Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999;91:429\u201333. [CrossRef].","journal-title":"J Natl Cancer Inst"},{"key":"400_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/03602530801952617","volume":"40","author":"U Gradhand","year":"2008","unstructured":"Gradhand U, Kim RB. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev. 2008;40:317\u201354. [CrossRef].","journal-title":"Drug Metab Rev"},{"key":"400_CR12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.bcp.2012.01.002","volume":"83","author":"K Natarajan","year":"2012","unstructured":"Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP\/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012;83:1084\u2013103. [CrossRef].","journal-title":"Biochem Pharmacol"},{"key":"400_CR13","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1360704","volume":"258","author":"SP Cole","year":"1992","unstructured":"Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650\u20134. [CrossRef].","journal-title":"Science"},{"key":"400_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1172\/JCI118535","volume":"97","author":"R Evers","year":"1996","unstructured":"Evers R, Zaman GJ, van Deemter L, Jansen H, Calafat J, Oomen LC, Oude Elferink RP, Borst P, Schinkel AH. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Investig. 1996;97:1211\u20138. [CrossRef].","journal-title":"J Clin Investig"},{"key":"400_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1440-1681.2009.05252.x","volume":"37","author":"YH Liu","year":"2010","unstructured":"Liu YH, Di YM, Zhou ZW, Mo SL, Zhou SF. Multidrug resistance-associated proteins and implications in drug development. Clin Exp Pharmacol Physiol. 2010;37:115\u201320. [CrossRef] [PubMed].","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"400_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA. New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"400_CR17","doi-asserted-by":"crossref","unstructured":"Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525\u201330.","DOI":"10.1038\/nature16064"},{"key":"400_CR18","doi-asserted-by":"publisher","unstructured":"Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer Stem Cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:5416923. https:\/\/doi.org\/10.1155\/2018\/5416923.","DOI":"10.1155\/2018\/5416923"},{"issue":"4","key":"400_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275\u201384.","journal-title":"Nat Rev Cancer"},{"key":"400_CR20","unstructured":"Shi Y, van der Meel R, Theek B, Oude Blenke E, Pieters EHE, Fens MHAM, et al. Complete regression of xenograft tumors upon targeted delivery of doxorubicin via hyaluronic acid-coated nanoparticles. ACS Nano. 2020;14(9):11620\u201332."},{"key":"400_CR21","doi-asserted-by":"publisher","unstructured":"Kumar M, Sharma S, Bhatnagar P, Tejaswi, Banik BK. Nanocarrier delivery of cisplatin and its patent studies. Curr Nanomed. 2026;16(1):37\u201350. https:\/\/doi.org\/10.2174\/0124681873332471241022152313.","DOI":"10.2174\/0124681873332471241022152313"},{"key":"400_CR22","doi-asserted-by":"publisher","first-page":"101549","DOI":"10.1016\/j.jddst.2020.101549","volume":"56","author":"S Saraf","year":"2020","unstructured":"Saraf S, Jain A, Tiwari A, Verma A, Panda PK, Jain SK. Advances in liposomal drug delivery to cancer: An overview. J Drug Delivery Sci Technol. 2020;56:101549. https:\/\/doi.org\/10.1016\/j.jddst.2020.101549.","journal-title":"J Drug Delivery Sci Technol"},{"key":"400_CR23","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1080\/10942912.2023.2247578","volume":"26","author":"N Akram","year":"2023","unstructured":"Akram N, Afzaal M, Saeed F, Shah YA, Faisal Z, Asghar A, Ateeq H, Nayik GA, Wani SH, Hussain M, Asif Shah M, Khaneghah AM. Liposomes: a promising delivery system for active ingredients in food and nutrition. Int J Food Prop. 2023;26:2476\u201392. https:\/\/doi.org\/10.1080\/10942912.2023.2247578.","journal-title":"Int J Food Prop"},{"key":"400_CR24","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.2174\/1389450122666210204203514","volume":"22","author":"NR Vandchali","year":"2021","unstructured":"Vandchali NR, Moadab F, Taghizadeh E, Tajbakhsh A, Gheibihayat SM. CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery. Curr Drug Targets. 2021;22:1750\u20139. https:\/\/doi.org\/10.2174\/1389450122666210204203514.","journal-title":"Curr Drug Targets"},{"key":"400_CR25","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3390\/ijms24032643","volume":"24","author":"S Wang","year":"2023","unstructured":"Wang S, Chen Y, Guo J, Huang Q. Liposomes for Tumor Targeted Therapy: A Review. Int J Mol Sci. 2023a;24:2643. https:\/\/doi.org\/10.3390\/ijms24032643.","journal-title":"Int J Mol Sci"},{"key":"400_CR26","doi-asserted-by":"crossref","unstructured":"Mahrous GR, Elkholy NS, Safwat G, Shafaa MW. Enhanced cytotoxic activity of beta carotene conjugated liposomes towards breast cancer cell line: comparative studies with cyclophosphamide. Anticancer Drugs. 2022;33:e462.","DOI":"10.1097\/CAD.0000000000001245"},{"key":"400_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.nano.2011.07.011","volume":"8","author":"SS Dhule","year":"2012","unstructured":"Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, He J, Alb A, John V, Pochampally R. Curcumin-loaded \u03b3-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine. 2012;8:440\u201351.","journal-title":"Nanomedicine"},{"key":"400_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3109\/10717544.2012.727500","volume":"19","author":"F Odeh","year":"2012","unstructured":"Odeh F, Ismail SI, Abu-Dahab R, Mahmoud IS, Al Bawab A. Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. Drug Deliv. 2012;19:371\u20137. https:\/\/doi.org\/10.3109\/10717544.2012.727500.","journal-title":"Drug Deliv"},{"key":"400_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2174\/1567201812666151027142412","volume":"13","author":"J Wolfram","year":"2016","unstructured":"Wolfram J, Scott B, Boom K, Shen J, Borsoi C, Suri K, Grande R, Fresta M, Celia C, Zhao Y, Shen H, Ferrari M. Hesperetin liposomes for cancer therapy. Curr Drug Deliv. 2016;13:711\u20139.","journal-title":"Curr Drug Deliv"},{"key":"400_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2012.11.031","volume":"330","author":"Y-Z Zhao","year":"2013","unstructured":"Zhao Y-Z, Dai D-D, Lu C-T, Chen L-J, Lin M, Shen X-T, Li X-K, Zhang M, Jiang X, Jin R-R, Li X, Lv H-F, Cai L, Huang P-T. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Lett. 2013;330:74\u201383. https:\/\/doi.org\/10.1016\/j.canlet.2012.11.031.","journal-title":"Cancer Lett"},{"key":"400_CR31","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/0885328220976331","volume":"35","author":"R Mahmoudi","year":"2021","unstructured":"Mahmoudi R, Hassandokht F, Ardakani MT, Karimi B, Roustazadeh A, Tarvirdipour S, Barmak MJ, Nikseresht M, Baneshi M, Mousavizadeh A, Shirazi MS, Alipour M, Bardania H. Intercalation of curcumin into liposomal chemotherapeutic agent augments apoptosis in breast cancer cells. J Biomater Appl. 2021;35:1005\u201318. https:\/\/doi.org\/10.1177\/0885328220976331.","journal-title":"J Biomater Appl"},{"key":"400_CR32","doi-asserted-by":"publisher","first-page":"102095","DOI":"10.1016\/j.nano.2019.102095","volume":"23","author":"Y Li","year":"2020","unstructured":"Li Y, Li X, Lu Y, Chaurasiya B, Mi G, Shi D, Chen D, Webster TJ, Tu J, Shen Y. Co-delivery of Poria cocos extract and doxorubicin as an all-in-one nanocarrier to combat breast cancer multidrug resistance during chemotherapy. Nanomedicine. 2020;23:102095. https:\/\/doi.org\/10.1016\/j.nano.2019.102095.","journal-title":"Nanomedicine"},{"key":"400_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ajps.2019.04.007","volume":"15","author":"R Zhang","year":"2020","unstructured":"Zhang R, Zhang Y, Zhang Y, Wang X, Gao X, Liu Y, Zhang X, He Z, Wang D, Wang Y. Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than Doxil. Asian J Pharm Sci. 2020b;15:385\u201396. https:\/\/doi.org\/10.1016\/j.ajps.2019.04.007.","journal-title":"Asian J Pharm Sci"},{"key":"400_CR34","doi-asserted-by":"publisher","first-page":"6983","DOI":"10.2147\/IJN.S318416","volume":"16","author":"M Barani","year":"2021","unstructured":"Barani M, Sangiovanni E, Angarano M, Rajizadeh MA, Mehrabani M, Piazza S, Gangadharappa HV, Pardakhty A, Mehrbani M, Dell\u2019Agli M, Nematollahi MH. Phytosomes as Innovative Delivery Systems for Phytochemicals: A Comprehensive Review of Literature. Int J Nanomed. 2021;16:6983\u20137022. https:\/\/doi.org\/10.2147\/IJN.S318416.","journal-title":"Int J Nanomed"},{"key":"400_CR35","doi-asserted-by":"publisher","first-page":"100540","DOI":"10.1016\/j.phyplu.2024.100540","volume":"4","author":"A Singh","year":"2024","unstructured":"Singh A, Srivastav S, Singh MP, Singh R, Kumar P, Kush P. Recent advances in phytosomes for the safe management of cancer. Phytomed Plus. 2024;4:100540. https:\/\/doi.org\/10.1016\/j.phyplu.2024.100540.","journal-title":"Phytomed Plus"},{"key":"400_CR36","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.3390\/ijms25084162","volume":"25","author":"L Toma","year":"2024","unstructured":"Toma L, Deleanu M, Sanda GM, Barb\u02d8alat\u02d8a T, Niculescu LS\u00b8, Sima AV, Stancu CS. Bioactive Compounds Formulated in Phytosomes Administered as Complementary Therapy for Metabolic Disorders. Int J Mol Sci. 2024;25:4162. https:\/\/doi.org\/10.3390\/ijms25084162.","journal-title":"Int J Mol Sci"},{"key":"400_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/polym14010093","volume":"14","author":"NA Alhakamy","year":"2021","unstructured":"Alhakamy NA, Fahmy UA, Eldin SMB, Ahmed OA, Aldawsari HM, Okbazghi SZ, Alfaleh MA, Abdulaal WH, Alamoudi AJ, Mady FM. Scorpion venom-functionalized quercetin phytosomes for breast cancer management: in vitro response surface optimization and anticancer activity against MCF-7 cells. Polymers. 2021a;14:93.","journal-title":"Polymers"},{"key":"400_CR38","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.7314\/apjcp.2014.15.13.5311","volume":"15","author":"M Sabzichi","year":"2014","unstructured":"Sabzichi M, Hamishehkar H, Ramezani F, Sharifi S, Tabasinezhad M, Pirouzpanah M, Ghanbari P, Samadi N. Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev. 2014;15:5311\u20136. https:\/\/doi.org\/10.7314\/apjcp.2014.15.13.5311.","journal-title":"Asian Pac J Cancer Prev"},{"key":"400_CR39","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.matpr.2020.11.047","volume":"42","author":"MP Murugesan","year":"2021","unstructured":"Murugesan MP, Venkata Ratnam M, Mengitsu Y, Kandasamy K. Evaluation of anti-cancer activity of phytosomes formulated from aloe vera extract. Mater Today Proc. 2021;42:631\u20136. https:\/\/doi.org\/10.1016\/j.matpr.2020.11.047.","journal-title":"Mater Today Proc"},{"key":"400_CR40","doi-asserted-by":"publisher","first-page":"104709","DOI":"10.1016\/j.jddst.2023.104709","volume":"86","author":"M Akanda","year":"2023","unstructured":"Akanda M, Mithu MSH, Douroumis D. Solid lipid nanoparticles: An effective lipid-based technology for cancer treatment. J Drug Delivery Sci Technol. 2023;86:104709. https:\/\/doi.org\/10.1016\/j.jddst.2023.104709.","journal-title":"J Drug Delivery Sci Technol"},{"key":"400_CR41","doi-asserted-by":"publisher","unstructured":"Vimala K, Kannan S. Chapter Ten- Phyto-drug conjugated nanomaterials enhance apoptotic activity in cancer. In: Donev, R, editor, Advances in Protein Chemistry and Structural Biology, Apoptosis in Health and Disease- Part A. Academic Press. 2021:275\u2013305. https:\/\/doi.org\/10.1016\/bs.apcsb.2020.12.003.","DOI":"10.1016\/bs.apcsb.2020.12.003"},{"key":"400_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.18231\/j.ctppc.2022.014","volume":"4","author":"MA Rahman","year":"2022","unstructured":"Rahman MA. Silymarin loaded solid lipid nanoparticles for oral delivery: Development, characterization and cytotoxic effect on breast cancer cells. Curr Trends Pharm Pharm Chem. 2022;4:75\u201382. https:\/\/doi.org\/10.18231\/j.ctppc.2022.014.","journal-title":"Curr Trends Pharm Pharm Chem"},{"key":"400_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s11033023-08848-w","author":"M Hatami","year":"2023","unstructured":"Hatami M, Kouchak M, Kheirollah A, Khorsandi L, Rashidi M. Quercetin loaded solid lipid nanoparticles exhibit antitumor activity and suppress the proliferation of triple-negative MDA-MB 231 breast cancer cells: implications for invasive breast cancer treatment. Mol Biol Rep. 2023. https:\/\/doi.org\/10.1007\/s11033023-08848-w.","journal-title":"Mol Biol Rep"},{"key":"400_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1208\/s12249-019-1301-7","volume":"20","author":"A Jain","year":"2019","unstructured":"Jain A, Sharma G, Thakur K, Raza K, Shivhare US, Ghoshal G, Katare OP. Beta-carotene-Encapsulated Solid Lipid Nanoparticles (BC-SLNs) as Promising Vehicle for Cancer: an Investigative Assessment. AAPS PharmSciTech. 2019;20:100. https:\/\/doi.org\/10.1208\/s12249-019-1301-7.","journal-title":"AAPS PharmSciTech"},{"key":"400_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.chemphyslip.2016.05.006","volume":"198","author":"R Radhakrishnan","year":"2016","unstructured":"Radhakrishnan R, Kulhari H, Pooja D, Gudem S, Bhargava S, Shukla R, Sistla R. Encapsulation of biophenolic phytochemical EGCG within lipid nanoparticles enhances its stability and cytotoxicity against cancer. Chem Phys Lipids. 2016;198:51\u201360. https:\/\/doi.org\/10.1016\/j.chemphyslip.2016.05.006.","journal-title":"Chem Phys Lipids"},{"key":"400_CR46","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3390\/molecules23071578","volume":"23","author":"W Wang","year":"2018","unstructured":"Wang W, Chen T, Xu H, Ren B, Cheng X, Qi R, Liu H, Wang Y, Yan L, Chen S, Yang Q, Chen C. Curcumin-Loaded Solid Lipid Nanoparticles Enhanced Anticancer Efficiency in Breast Cancer. Molecules. 2018;23:1578. https:\/\/doi.org\/10.3390\/molecules23071578.","journal-title":"Molecules"},{"key":"400_CR47","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.1016\/j.onano.2022.100064","volume":"8","author":"VH Nguyen","year":"2022","unstructured":"Nguyen VH, Thuy VN, Van TV, Dao AH, Lee B-J. Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration. OpenNano. 2022;8:100064. https:\/\/doi.org\/10.1016\/j.onano.2022.100064.","journal-title":"OpenNano"},{"key":"400_CR48","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jddst.2017.03.001","volume":"39","author":"A Babazadeh","year":"2017","unstructured":"Babazadeh A, Ghanbarzadeh B, Hamishehkar H. Formulation of food grade nanostructured lipid carrier (NLC) for potential applications in medicinal-functional foods. J Drug Delivery Sci Technol. 2017;39:50\u20138. https:\/\/doi.org\/10.1016\/j.jddst.2017.03.001.","journal-title":"J Drug Delivery Sci Technol"},{"key":"400_CR49","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3390\/ph16081108","volume":"16","author":"S Ahalwat","year":"2023","unstructured":"Ahalwat S, Bhatt DC, Rohilla S, Jogpal V, Sharma K, Virmani T, Kumar G, Alhalmi A, Alqahtani AS, Noman OM, Almoiliqy M. Mannose functionalized isoniazid-loaded nanostructured lipid carriers for pulmonary delivery. in vitro prospects and in vivo therapeutic efficacy assessment. Pharmaceuticals. 2023;16:1108. https:\/\/doi.org\/10.3390\/ph16081108.","journal-title":"Pharmaceuticals"},{"key":"400_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jddst.2019.02.017","volume":"51","author":"VR Salvi","year":"2019","unstructured":"Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Delivery Sci Technol. 2019;51:255\u201367. https:\/\/doi.org\/10.1016\/j.jddst.2019.02.017.","journal-title":"J Drug Delivery Sci Technol"},{"key":"400_CR51","doi-asserted-by":"publisher","first-page":"119401","DOI":"10.1016\/j.carbpol.2022.119401","volume":"288","author":"TH Truong","year":"2022","unstructured":"Truong TH, Alcantara KP, Bulatao BPI, Sorasitthiyanukarn FN, Muangnoi C, Nalinratana N, Vajragupta O, Rojsitthisak P, Rojsitthisak P. Chitosan coated nanostructured lipid carriers for transdermal delivery of tetrahydrocurcumin for breast cancer therapy. Carbohydr Polym. 2022;288:119401. https:\/\/doi.org\/10.1016\/j.carbpol.2022.119401.","journal-title":"Carbohydr Polym"},{"key":"400_CR52","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2217\/nnm-2020-0277","volume":"15","author":"B Mangla","year":"2020","unstructured":"Mangla B, Neupane YR, Singh A, Kumar P, Shafi S, Kohli K. Lipid-nanopotentiated combinatorial delivery of tamoxifen and sulforaphane: ex vivo, in vivo and toxicity studies. Nanomed (lond). 2020;15:2563\u201383. https:\/\/doi.org\/10.2217\/nnm-2020-0277.","journal-title":"Nanomed (lond)"},{"key":"400_CR53","doi-asserted-by":"publisher","unstructured":"Palei NN, Mounika G, Mohanta BC, Rajangam J. Quercetin and Morin dual drug loaded nanostructured lipid carriers: formulation and in vitro cytotoxicity study on MCF7 breast cancer cells. J Dispers Sci Technol. 2023;1\u20139. https:\/\/doi.org\/10.1080\/01932691.2023.2248261.","DOI":"10.1080\/01932691.2023.2248261"},{"key":"400_CR54","doi-asserted-by":"publisher","first-page":"110876","DOI":"10.1016\/j.biopha.2020.110876","volume":"132","author":"EB Lages","year":"2020","unstructured":"Lages EB, Fernandes RS, Silva JdeO, de Souza \u02c6AM, Cassali GD, de Barros ALB, Ferreira M, L.A. Co-delivery of doxorubicin, docosahexaenoic acid, and-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity. Biomed Pharmacother. 2020;132:110876. https:\/\/doi.org\/10.1016\/j.biopha.2020.110876.","journal-title":"Biomed Pharmacother"},{"key":"400_CR55","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3390\/pharmaceutics14091771","volume":"14","author":"A Alhalmi","year":"2022","unstructured":"Alhalmi A, Amin S, Khan Z, Beg S, Al kamaly O, Saleh A, Kohli K. Nanostructured lipid carrier-based codelivery of raloxifene and naringin: formulation, optimization, in vitro, ex vivo, in vivo assessment, and acute toxicity studies. Pharmaceutics. 2022;14:1771. https:\/\/doi.org\/10.3390\/pharmaceutics14091771.","journal-title":"Pharmaceutics"},{"key":"400_CR56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s11671-023-03943-0","volume":"18","author":"G Unnikrishnan","year":"2023","unstructured":"Unnikrishnan G, Joy A, Megha M, Kolanthai E, Senthilkumar M. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review. Discover Nano. 2023;18:157. https:\/\/doi.org\/10.1186\/s11671-023-03943-0.","journal-title":"Discover Nano"},{"key":"400_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12951-024-02701-3","volume":"22","author":"S Narayana","year":"2024","unstructured":"Narayana S, Gowda BHJ, Hani U, Shimu SS, Paul K, Das A, Ashique S, Ahmed MG, Tarighat MA, Abdi G. Inorganic nanoparticle-based treatment approaches for colorectal cancer: recent advancements and challenges. J Nanobiotechnol. 2024;22:427. https:\/\/doi.org\/10.1186\/s12951-024-02701-3.","journal-title":"J Nanobiotechnol"},{"key":"400_CR58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.tifs.2016.06.003","volume":"54","author":"D Arora","year":"2016","unstructured":"Arora D, Jaglan S. Nanocarriers based delivery of nutraceuticals for cancer prevention and treatment: A review of recent research developments. Trends Food Sci Technol. 2016;54:114\u201326. https:\/\/doi.org\/10.1016\/j.tifs.2016.06.003.","journal-title":"Trends Food Sci Technol"},{"key":"400_CR59","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.2174\/1381612821666150901103032","volume":"21","author":"J Zhao","year":"2015","unstructured":"Zhao J, Lee P, Wallace M, Melancon M. Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity. CPD. 2015;21:4240\u201351. https:\/\/doi.org\/10.2174\/1381612821666150901103032.","journal-title":"CPD"},{"key":"400_CR60","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/1061186X.2017.1400553","volume":"26","author":"A Sharma","year":"2018","unstructured":"Sharma A, Goyal AK, Rath G. Recent advances in metal nanoparticles in cancer therapy. J Drug Target. 2018;26:617\u201332. https:\/\/doi.org\/10.1080\/1061186X.2017.1400553.","journal-title":"J Drug Target"},{"key":"400_CR61","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s12668-019-00660-w","volume":"9","author":"NS Elbialy","year":"2019","unstructured":"Elbialy NS, Abdelfatah EA, Khalil WA. Antitumor Activity of Curcumin Green Synthesized Gold Nanoparticles. Vitro Study Bionanosci. 2019;9:813\u201320. https:\/\/doi.org\/10.1007\/s12668-019-00660-w.","journal-title":"Vitro Study Bionanosci"},{"key":"400_CR62","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/cpr.12296","volume":"49","author":"S Balakrishnan","year":"2016","unstructured":"Balakrishnan S, Bhat FA, Raja Singh P, Mukherjee S, Elumalai P, Das S, Patra CR, Arunakaran J. Gold nanoparticle\u2013conjugated quercetin inhibits epithelial\u2013mesenchymal transition, angiogenesis and invasiveness via EGFR\/VEGFR 2-mediated pathway in breast cancer. Cell Prolif. 2016;49:678\u201397. https:\/\/doi.org\/10.1111\/cpr.12296.","journal-title":"Cell Prolif"},{"key":"400_CR63","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2217\/nnm-2019-0429","volume":"15","author":"FA Khan","year":"2020","unstructured":"Khan FA, Lammari N, Siar M, Alkhater AS, Asiri KM, Akhtar S, Almansour S, Alamoudi I, Haroun W, Louaer W, Meniai W, Elaissari AH, A. Quantum dots encapsulated with curcumin inhibit the growth of colon cancer, breast cancer and bacterial cells. Nanomed (lond). 2020;15:969\u201380. https:\/\/doi.org\/10.2217\/nnm-2019-0429.","journal-title":"Nanomed (lond)"},{"key":"400_CR64","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/ph15111343","volume":"15","author":"G Kumar","year":"2022","unstructured":"Kumar G, Virmani T, Pathak K, Kamaly OA, Saleh A. Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability. Vitro Ex Vivo Evaluation Pharmaceuticals. 2022b;15:1343. https:\/\/doi.org\/10.3390\/ph15111343.","journal-title":"Vitro Ex Vivo Evaluation Pharmaceuticals"},{"key":"400_CR65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.partic.2021.05.009","volume":"64","author":"RJ Wilson","year":"2022","unstructured":"Wilson RJ, Li Y, Yang G, Zhao C-X. Nanoemulsions for drug delivery. Particuology Nat Biomim Particles Bio-Applications. 2022;64:85\u201397. https:\/\/doi.org\/10.1016\/j.partic.2021.05.009.","journal-title":"Particuology Nat Biomim Particles Bio-Applications"},{"key":"400_CR66","doi-asserted-by":"publisher","unstructured":"Kumar G, Virmani T, Pathak K, Alhalmi A. A revolutionary blueprint for mitigation of hypertension via nanoemulsion. BioMed Res Int. 2022;2022(1);4109874. https:\/\/doi.org\/10.1155\/2022\/4109874.","DOI":"10.1155\/2022\/4109874"},{"key":"400_CR67","doi-asserted-by":"publisher","first-page":"111526","DOI":"10.1016\/j.colsurfb.2020.111526","volume":"200","author":"O Tarhan","year":"2021","unstructured":"Tarhan O, Spotti MJ. Nutraceutical delivery through nano-emulsions: General aspects, recent applications and patented inventions. Colloids Surf B Biointerfaces. 2021;200:111526. https:\/\/doi.org\/10.1016\/j.colsurfb.2020.111526.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"400_CR68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10068019-00731-4","volume":"29","author":"SJ Choi","year":"2020","unstructured":"Choi SJ, McClements DJ. Nanoemulsions as delivery systems for lipophilic nutraceuticals: strategies for improving their formulation, stability, functionality and bioavailability. Food Sci Biotechnol. 2020;29:149\u201368. https:\/\/doi.org\/10.1007\/s10068019-00731-4.","journal-title":"Food Sci Biotechnol"},{"key":"400_CR69","doi-asserted-by":"publisher","first-page":"100279","DOI":"10.1016\/j.chphi.2023.100279","volume":"7","author":"H Yadav","year":"2023","unstructured":"Yadav H, Rout D, Upadhyaya AK, Agarwala P, Sharma A, Sasmal DK. Carbon quantum dots for efficient delivery of curcumin in live cell. Chem Phys Impact. 2023a;7:100279. https:\/\/doi.org\/10.1016\/j.chphi.2023.100279.","journal-title":"Chem Phys Impact"},{"key":"400_CR70","doi-asserted-by":"publisher","first-page":"102907","DOI":"10.1016\/j.jddst.2021.102907","volume":"66","author":"J Ceramella","year":"2021","unstructured":"Ceramella J, Groo A-C, Iacopetta D, S\u00b4 eguy L, Mariconda A, Puoci F, Saturnino C, Leroy F, Since M, Longo P, Malzert-Fr\u00b4 eon A, Sinicropi MS. A winning strategy to improve the anticancer properties of Cisplatin and Quercetin based on the nanoemulsions formulation. J Drug Delivery Sci Technol. 2021;66:102907. https:\/\/doi.org\/10.1016\/j.jddst.2021.102907.","journal-title":"J Drug Delivery Sci Technol"},{"key":"400_CR71","doi-asserted-by":"publisher","first-page":"7205241","DOI":"10.1155\/2022\/7205241","volume":"2022","author":"A Sharma","year":"2022","unstructured":"Sharma A, Virmani T, Pathak V, Sharma A, Pathak K, Kumar G, Pathak D. Artificial Intelligence-Based Data-Driven Strategy to Accelerate Research, Development, and Clinical Trials of COVID Vaccine. Biomed Res Int. 2022a;2022:7205241. https:\/\/doi.org\/10.1155\/2022\/7205241.","journal-title":"Biomed Res Int"},{"key":"400_CR72","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1007\/s11095-016-2004-3","volume":"33","author":"P Fonte","year":"2016","unstructured":"Fonte P, Andrade F, Azevedo C, Pinto J, Seabra V, van de Weert M, Reis S, Sarmento B. Effect of the Freezing Step in the Stability and Bioactivity of Protein-Loaded PLGA Nanoparticles Upon Lyophilization. Pharm Res. 2016;33:2777\u201393. https:\/\/doi.org\/10.1007\/s11095-016-2004-3.","journal-title":"Pharm Res"},{"key":"400_CR73","doi-asserted-by":"publisher","unstructured":"Kumar G, Virmani T, Sharma A, Pathak K. Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers. Pharmaceutics. 2023;15. https:\/\/doi.org\/10.3390\/pharmaceutics15030889.","DOI":"10.3390\/pharmaceutics15030889"},{"key":"400_CR74","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/nano10071403","volume":"10","author":"B Begines","year":"2020","unstructured":"Begines B, Ortiz T, P\u00b4erez-Aranda M, Mart\u00ednez G, Merinero M, Arg\u00fcelles-Arias F, Alcudia A. Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials (basel). 2020;10:1403. https:\/\/doi.org\/10.3390\/nano10071403.","journal-title":"Nanomaterials (basel)"},{"key":"400_CR75","doi-asserted-by":"publisher","unstructured":"Virmani R, Sharma A, Sharma A, Kumar G, Virmani T, Mukherjee S. 17- Nanotechnology in pulmonary tissue engineering. In: Mondal A, Nayak AK, Chakraborty P, editors. Nanostructured Materials for Tissue Engineering, Nanotechnology in Biomedicine. Elsevier; 2023. pp. 537\u201356. https:\/\/doi.org\/10.1016\/B978-0-323-95134-0.00017-1.","DOI":"10.1016\/B978-0-323-95134-0.00017-1"},{"key":"400_CR76","doi-asserted-by":"publisher","first-page":"110515","DOI":"10.1016\/j.colsurfb.2019.110515","volume":"184","author":"MA Vakilinezhad","year":"2019","unstructured":"Vakilinezhad MA, Amini A, Dara T, Alipour S. Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation. Colloids Surf B Biointerfaces. 2019;184:110515. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.110515.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"400_CR77","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1016\/j.bbiosy.2021.100022","volume":"3","author":"I Khan","year":"2021","unstructured":"Khan I, Sarkar B, Joshi G, Nakhate KT, Ajazuddin, Mantha AK, Kumar R, Kaul A, Chaturvedi S, Mishra AK, Gupta U. Biodegradable nanoparticulate co delivery of flavonoid and doxorubicin: Mechanistic exploration and evaluation of anticancer effect in vitro and in vivo. Biomaterials Biosystems. 2021;3:100022. https:\/\/doi.org\/10.1016\/j.bbiosy.2021.100022.","journal-title":"Biomaterials Biosystems"},{"key":"400_CR78","doi-asserted-by":"publisher","first-page":"104050","DOI":"10.1016\/j.jddst.2022.104050","volume":"79","author":"X Lin","year":"2023","unstructured":"Lin X, Wang Q, Du S, Guan Y, Qiu J, Chen X, Yuan D, Chen T. Nanoparticles for co-delivery of paclitaxel and curcumin to overcome chemoresistance against breast cancer. J Drug Delivery Sci Technol. 2023;79:104050. https:\/\/doi.org\/10.1016\/j.jddst.2022.104050.","journal-title":"J Drug Delivery Sci Technol"},{"key":"400_CR79","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/ph17060677","volume":"17","author":"K Hristova-Panusheva","year":"2024","unstructured":"Hristova-Panusheva K, Xenodochidis C, Georgieva M, Krasteva N. Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology. Pharmaceuticals (Basel). 2024;17:677. https:\/\/doi.org\/10.3390\/ph17060677.","journal-title":"Pharmaceuticals (Basel)"},{"key":"400_CR80","doi-asserted-by":"publisher","first-page":"113998","DOI":"10.1016\/j.biopha.2022.113998","volume":"157","author":"J Chen","year":"2023","unstructured":"Chen J, Cong X. Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects. Biomed Pharmacother. 2023;157:113998. https:\/\/doi.org\/10.1016\/j.biopha.2022.113998.","journal-title":"Biomed Pharmacother"},{"key":"400_CR81","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.3390\/pharmaceutics15092216","volume":"15","author":"VB Junyaprasert","year":"2023","unstructured":"Junyaprasert VB, Thummarati P. Innovative Design of Targeted Nanoparticles: Polymer-Drug Conjugates for Enhanced Cancer Therapy. Pharmaceutics. 2023;15:2216. https:\/\/doi.org\/10.3390\/pharmaceutics15092216.","journal-title":"Pharmaceutics"},{"key":"400_CR82","doi-asserted-by":"publisher","first-page":"119449","DOI":"10.1016\/j.ijpharm.2020.119449","volume":"585","author":"J Kazi","year":"2020","unstructured":"Kazi J, Sen R, Ganguly S, Jha T, Ganguly S, Chatterjee Debnath M. Folate decorated epigallocatechin-3-gallate (EGCG) loaded PLGA nanoparticles; in-vitro and in-vivo targeting efficacy against MDA-MB-231 tumor xenograft. Int J Pharm. 2020;585:119449. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119449.","journal-title":"Int J Pharm"},{"key":"400_CR83","doi-asserted-by":"publisher","first-page":"41872","DOI":"10.1021\/acsomega.2c01829","volume":"7","author":"F Farabegoli","year":"2022","unstructured":"Farabegoli F, Granja A, Magalh\u02dcaes J, Purgato S, Voltattorni M, Pinheiro M. Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines. ACS Omega. 2022;7:41872\u201381. https:\/\/doi.org\/10.1021\/acsomega.2c01829.","journal-title":"ACS Omega"},{"key":"400_CR84","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1080\/10717544.2021.1963351","volume":"28","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Q, Feng W, Yuan Q, Qi X, Chen S, Yao P, Dai Q, Xia P, Zhang D, Sun F. Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment. Drug Deliv. 2021b;28:1695\u2013708. https:\/\/doi.org\/10.1080\/10717544.2021.1963351.","journal-title":"Drug Deliv"},{"key":"400_CR85","doi-asserted-by":"publisher","first-page":"102603","DOI":"10.1016\/j.jddst.2021.102603","volume":"65","author":"F Meng","year":"2021","unstructured":"Meng F, Liu F, Lan M, Zou T, Li L, Cai T, Cai Y. Preparation and evaluation of folate-modified albumin baicalin-loaded nanoparticles for the targeted treatment of breast cancer. J Drug Delivery Sci Technol. 2021;65:102603. https:\/\/doi.org\/10.1016\/j.jddst.2021.102603.","journal-title":"J Drug Delivery Sci Technol"},{"key":"400_CR86","doi-asserted-by":"publisher","first-page":"8096","DOI":"10.1039\/D3TB00278K","volume":"11","author":"C Yan","year":"2023","unstructured":"Yan C, Zhang J, Huang M, Xiao J, Li N, Wang T, Ling R. Design, strategies, and therapeutics in nanoparticle-based siRNA delivery systems for breast cancer. J Mater Chem B. 2023;11:8096\u2013116.","journal-title":"J Mater Chem B"},{"key":"400_CR87","doi-asserted-by":"publisher","first-page":"1271420","DOI":"10.3389\/fbioe.2023.1271420","volume":"11","author":"W Zeng","year":"2023","unstructured":"Zeng W, Luo Y, Gan D, Zhang Y, Deng H, Liu G. Advances in doxorubicin-based nano-drug delivery system in triple-negative breast cancer. Front Bioeng Biotechnol. 2023;11:1271420.","journal-title":"Front Bioeng Biotechnol"},{"key":"400_CR88","doi-asserted-by":"publisher","first-page":"32956","DOI":"10.1039\/D2RA02005J","volume":"12","author":"MA Subhan","year":"2022","unstructured":"Subhan MA. Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics. RSC Adv. 2022;12:32956\u201378.","journal-title":"RSC Adv"},{"issue":"9","key":"400_CR89","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.3390\/ijms22094673","volume":"22","author":"V Gote","year":"2021","unstructured":"Gote V, Nookala AR, Bolla PK, Pal D. Drug resistance in metastatic breast cancer: Tumor-targeted nanomedicine to the rescue. Int J Mol Sci. 2021;22(9):4673.","journal-title":"Int J Mol Sci"},{"key":"400_CR90","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1039\/D3NA00965C","volume":"6","author":"LL Panigrahi","year":"2024","unstructured":"Panigrahi LL, Samal P, Sahoo SR, Sahoo B, Pradhan AK, Mahanta S, Arakha M. Nanoparticle-mediated diagnosis, treatment, and prevention of breast cancer. Nanoscale Adv. 2024;6:3699\u2013713.","journal-title":"Nanoscale Adv"},{"key":"400_CR91","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s11671-024-04122-5","volume":"19","author":"P Velapure","year":"2024","unstructured":"Velapure P, Kansal D, Bobade C. Tumor microenvironment\u2013responsive nanoformulations for breast cancer. Discover Nano. 2024;19:212.","journal-title":"Discover Nano"},{"key":"400_CR92","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10565-025-10067-x","volume":"41","author":"J Gao","year":"2025","unstructured":"Gao J, Ma N, Ni S, Han X. Intersection of ferroptosis and nanomaterials brings benefits to breast cancer. Cell Biol Toxicol. 2025;41:119.","journal-title":"Cell Biol Toxicol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00400-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00400-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00400-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:54:26Z","timestamp":1787748866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00400-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00400-8","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"63"}}